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Microalbuminuria in hypertension is not a determinant of insu- Microalbuminuria (MA) is present in 10 to 40% of
lin resistance. patients with essential hypertension [1–3]. The presence
Background. Microalbuminuria (MA) clusters with meta- of MA predicts increased risk of cardiovascular and renalbolic derangements linked to the insulin resistance syndrome,
disease in type 2 diabetes [4, 5] and increased risk of car-and is associated with increased risk of cardiovascular disease
diovascular disease in hypertension as well [1, 3, 6–8].in both diabetes and hypertension. This study questioned if
MA, reflecting endothelial damage, is directly linked to im- Hypertension is often associated with overweight, insulin
paired insulin action. resistance and compensatory hyperinsulinemia, glucose
Methods. MA was measured in two 24-hour urine samples
intolerance, and dyslipidemia [9], a condition known asin 84 persons with untreated hypertension recruited from a
the insulin resistance syndrome [10]. MA in hypertensionpopulation survey (diastolic blood pressures 90 to 105 mm Hg).
Thirty-one percent had MA values 20 g/min (MA group, is related to blood pressure [2, 11, 12], but associations
N  26), and these were matched according to age, gender, have also been found to insulin resistance [13, 14], hyper-
and body-mass index with hypertensive persons without MA insulinemia [6, 15, 16], levels of triglycerides and apolipo-(non-MA group, N  32) for comparison of the metabolic
protein B [15, 17], as well as with body mass index (BMI)profile. Insulin sensitivity was measured with clamp techniques.
[18, 19]. Factors linking insulin resistance and MA haveResults. The MA and non-MA groups were similar in their
fasting and post-load glucose and insulin levels, in the first been suggested to be lipid-induced intrarenal vasculopa-
(930  594 vs. 1097  707 pmol/L) and second (1111  662 thy [20, 21], insulin derived changes in renal hemodynam-
vs. 1163  702 pmol/L) phases of insulin release during a ics [22, 23], insulin induced permeability of the glomeru-hyperglycemic clamp, and in their insulin sensitivity indices
lar basement membrane [24], and glomerular protein(0.16  0.10 vs. 0.17  0.13, P  0.3 for all). The MA group
had higher systolic blood pressure (157  13 vs. 150  12 leakage due to accumulation of advanced glycation end
mm Hg, P  0.05) and a higher serum level of circulating products (AGEs) [25, 26].
advanced glycation end products (AGEs; 11.0  3.0 vs. 7.9  However, the association between MA and insulin
3.5 U/mL, P  0.05) than the controls. No associations were
resistance in essential hypertension is not clear. Epidemi-found between MA and the insulin sensitivity index, or glucose
ological studies investigating the relationship between MAand insulin levels. Weak associations were found with systolic
blood pressure (r  0.25, P  0.05), AGEs (r  0.27, P  and the insulin resistance syndrome have shown conflict-
0.05), and smoking habits (r  0.39, P  0.01). ing results [27, 28]. Case-control studies on this topic
Conclusion: In hypertension, MA is not a determinant of suffer from not being population-based [13], not applyinginsulin resistance, provided confounding factors such as degree
the clamp technique to assess insulin resistance [29, 30],of adiposity are carefully controlled.
or failure to correct sufficiently for confounders such as
the degree and distribution of adiposity [30], smoking
[31], physical activity [32], or treatment with antihyper-
tensive drugs [13, 19].
We conducted a population-based study to examine
insulin resistance and the metabolic profile in persons withKey words: cardiovascular disease, blood pressure, hyperinsulinemia,
glucose intolerance, dyslipidemia, essential hypertension. long-standing, non-treated hypertension with and without
MA. The aim of the present study was to examine if MA inReceived for publication February 28, 2001
essential hypertension is associated the metabolic changesand in revised form July 24, 2001
Accepted for publication November 27, 2001 seen with insulin resistance, or must be regarded solely
as an marker for vascular dysfunction [33] that predicts 2002 by the International Society of Nephrology
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coronary artery disease (CAD) independently of the 10, 15, 20, 40, 60, 80, 100, 120, 140, 160, and 180 minutes.
Mean insulin levels achieved during 120 to 180 minutesmetabolic profile.
of the clamp were 270  156 pmol/L in the MA group
and 288  174 pmol/L in the non-MA group (P  0.5).
METHODS
The insulin sensitivity index (ISI) was calculated by di-
Participants viding mean glucose infusion rate at 120, 140, 160 and
180 minutes of the hyperglycemic clamp (mol/kg/min)Eighty-four hypertensive persons who participated in
a 1987 population screening program, the Tromsø Study by average plasma insulin concentration (pmol/L) during
the same period of time. We also used a euglycemic,[34], were screened for participation in the present study.
Details about the selection criteria have been published hyperinsulinemic clamp [37] on 19 of the participants to
confirm that the insulin sensitivity indexes obtained frompreviously [35]. None were on hypertensive treatment,
and all appeared healthy on clinical examination. None the two clamp techniques were comparable [38]. Pear-
son’s correlation coefficient for the insulin sensitivityhad ischemic heart disease or type II diabetes mellitus.
Hypertension was defined as diastolic blood pressure index calculated by the two clamp techniques was r 
0.76 (P  0.0001); the slope ( SE) of the regressionabove 90 mm Hg. Persons with systolic blood pressure
above 190 mm Hg or diastolic blood pressure above 110 line was 2.74  0.56 (P  0.0001), and the intercept was
0.04  0.05 (P  0.48).mm Hg were excluded. The subjects collected 24-hour
urine on two occasions, one to two weeks apart. MA Plasma glucose concentrations were analyzed bedside
with a Yellow Spring Instruments glucose analyzer (2300was determined by immunophelometric assay (Behring
Institute). If the average MA excretion was 20 to 200 STAT PLUS; Yellow Springs, OH, USA). Plasma insulin
was measured by radioimmunoassay [39]. NEFA wereg/min, the hypertensives were defined to have MA.
Thirty-one percent of the 84 hypertensive subjects had analyzed by an acyl-CoA oxydase-based colorimetric kit
(Wako Nefa C Kit, Osaka, Japan). Insulin action on theMA (MA group). These were matched with hyperten-
sives without MA (non-MA group) according to age, suppression of NEFA during the hyperglycemic clamp
[40], mimicking the postprandial situation, was calcu-BMI, and gender. Thus, 20 males and 38 females, age
range 27 to 66 years, were included in the present study. lated by the formula
All participants completed a questionnaire about family
{([NEFA]300  [NEFA]120180)/[NEFA]300}  100history, physical activity, smoking, and alcohol habits.
The study was approved by the Regional Board of Re- where [NEFA]300 is mean baseline concentration at
30 and 0 minutes before initiation of the hyperglyce-search Ethics, and each person gave written informed
consent before participating. mic clamp, and [NEFA]120180 is the mean of the NEFA
concentration at 120 and 180 minutes of the clamp. Se-
Clinical and laboratory measurements rum triglycerides were measured on a Hitachi 737 Auto-
matic Analyzer (Tokyo, Japan), with a kit from Boeh-Blood pressure was measured three times on two
separate days using a mercury sphygmomanometer. The ringer Mannheim (Mannheim, Germany). Glycosylated
hemoglobin A1C levels were measured by a liquid chro-mean of the measurements was used in the analyses. The
waist-to-hip ratio was calculated as body circumference matographic procedure (Diamat System; Bio-Rad La-
boratories GmbH, Munich, Germany). Serum levels ofat the level midway between the inferior border of the
rib cage and superior border of the iliac crest, divided AGEs were measured to test if increments of these com-
pounds could be associated with MA, possibly reflectingby the maximal circumference of the buttocks.
The metabolic studies were started at 8 am after an increased membrane permeability. AGEs were measured
by a competitive fluorescence immunoassay method [41].overnight fast. Arterialized blood was drawn from a can-
nulated dorsal hand vein, where the hand was placed in Total protein concentration was measured by the Biuret
method (Boehringer), and serum AGEs were corrected fora heating device at 65C [36]. Glucose and insulin kinetics
were assessed with an oral glucose tolerance test and a variations in total protein concentration by the following
formula: (AGE, U/mL)/(sample protein concentration/hyperglycemic clamp. Glucose and insulin responses
after oral glucose challenge were calculated as arbitrary mean protein concentration of all sera measured).
Plasma levels of fibrinogen, coagulation factor VII activ-incremental area units over the two-hour sampling time.
The hyperglycemic clamp technique [37, 38] was used ity, plasminogen activator inhibitor type 1 (PAI-1) activ-
ity, and tissue plasminogen activator (tPA) activity werefor assessment of insulin sensitivity to glucose disposal
and suppression of serum non-esterified fatty acids measured because changes of these variables may indi-
cate endothelial dysfunction [33] reflected by alterations(NEFA) under physiological insulin stimulation. Plasma
glucose levels were kept at 10 mmol/L for three hours in the coagulation and fibrinolytic systems. Determina-
tion of plasma PAI-1 activity was done with a commercialby a variable glucose infusion, and blood samples for
insulin measurements were drawn at 30, 0, 2.5, 5, 7.5, two-stage indirect enzymatic kit (Spectrolyse Biopool
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Table 2. Hematologic and lipid variables in hypertensive personsTable 1. Clinical characteristics
with and without microalbuminuria (MA)
Non-MA MA P value
Non-MA MA P value
N 32 26
Gender male/female 10/22 10/16 0.6 Creatinine lmol/L 7814 7819 0.9
Fibrinogen g/L 2.290.68 2.250.70 0.8Age years 533 567 0.2
Body mass index kg/m2 27.65.5 27.53.1 0.9 Factor VII % 10125 10842 0.5
PAI-1 U/mL 11.97.6 14.210.0 0.8Waist-to-hip ratio 1.000.08 1.030.12 0.4
Systolic blood pressure mm Hg 15013 15712 0.05 tPA mU/mL 0.380.26 0.310.21 0.4
Triglycerides mmol/L 1.350.62 1.430.83 0.8Diastolic blood pressure mm Hg 986 995 0.3
Smoking % VLDL cholesterol mmol/L 0.630.29 0.670.39 0.7
LDL cholesterol mmol/L 4.150.97 4.090.77 0.80 cigarettes/day 79 57
1–19 cigarettes/day 17 27 0.1 HDL cholesterol mmol/L 1.300.26 1.350.50 0.7
Fasting NEFA lmol/L 469145 470160 0.920 cigarettes/day 4 16
Alcohol intake % NEFA levels during
clamp lmol/L 7135 6136 0.40–9 g/day 67 56
10–19 g/day 26 28 0.6 NEFA suppression
during clamp % 857 878 0.420 g/day 7 16
Physical activity level % Values are mean SD. Abbreviations are: non-MA, hypertensive persons with
Inactive, 0.5 h/week 39 58 microalbuminuria 20 g/min; MA, hypertensive persons with microalbumin-
Some, 0.5–2 h/week 39 25 0.4 uria20 g/min; PAI-1, plaminogen activator inhibitor; tPA, tissue plasminogen
Regular, 2 h/week 22 17 activity; NEFA, non-esterified fatty acids; NEFA levels during clamp, levels of non-
esterified fatty acids during the hyperinsulinemia occurring at 120 to 180 minutesValues are mean  SD. Definitions are: non-MA, hypertensive persons with of a hyperglycemic clamp; NEFA suppression during clamp, percent reduction ofmicroalbuminuria 20 g/min; MA, hypertensive persons with microalbumin- non-esterified fatty acid leves at 120 to 180 minutes of a hyperglycemic clamp;uria 20 g/min. VLDL, very low-density lipoprotein; LDL, low-density lipoprotein; HDL, high-
density lipoprotein.
AB) [42, 43]. tPA activity was determined according to
Wiman, Mellbring and Ranby [44]. Plasma fibrinogen MA group. There were three patients in the MA group
was measured with an ACL 3000 coagulation system and two patients in the non-MA group with a family
(Instrumentation Laboratory SpA). The percent of Fac- history of diabetes mellitus. The two groups were well
tor VII activity was measured with the same instrument. balanced for gender, age, body mass index, waist-to-hip
ratio, physical activity level, and alcohol consumption
Statistical analysis (Table 1). There were more heavy smokers in the MA
All data were checked with regard to frequency distri- group compared to the non-MA group, but the two
bution and transformed to normal distribution by loga- groups did not differ significantly in smoking habits (P
rithmic transformation when appropriate. Statistical anal- 0.1, Table 1). Systolic blood pressure was higher in the
ysis was performed using MA as a categorical variable, MA group than in the non-MA group (157  12 vs.
as well as a continuous variable after log transformation. 150 13 mm Hg, respectively, P 0.05). No differences
Two-sample t test was used to test differences between were observed in diastolic blood pressure (Table 1).
the MA and the non-MA groups. Group frequency dif- Plasma concentrations of creatinine, sodium, potassium
ferences in categorical data obtained from the question- and chloride in the MA and non-MA groups were 78.1
naire were tested with the Chi-square test. Correlations 19.2 vs. 77.8  13.9 mol/L (P  0.9), 140  3 vs. 140 
were computed by using the Pearson correlation coeffi- 3 mEq/L (P  0.8), 3.9  0.3 vs. 3.9  0.2 mEq/L (P 
cients and univariate linear regression models. Indepen- 0.9), and 109 3 vs. 107 3 mEq/L (P 0.1), respectively.
dent relations were tested in multiple linear regression
models. Data are given as mean  standard deviation Lipid metabolism
(SD) unless otherwise noted. P  0.05 was considered
The lipid profile was almost identical in the two studystatistically significant. The data were analyzed using the
groups (Table 2). Levels of triglycerides, very low-den-SAS software package (Statistical Analysis System,
sity lipoprotein (VLDL), low-density lipoprotein (LDL),Cary, NC, USA) [45].
and high-density lipoprotein (HDL) cholesterol in the
group of hypertensive subjects with and without MA
RESULTS were 1.43  0.83 and 1.35  0.62 mmol/L (P  0.8),
0.67  0.39 and 0.63  29 mmol/L (P  0.7), 4.09 Median 24-hour albumin excretion was 37 g/min
0.77 and 4.15  0.97 (P  0.8), and 1.35  0.50 and(range 21 to 200 g/min) in the MA group and 11 g/
1.30 0.26 (P 0.7), respectively. No group differencesmin (range 7 to 15 g/min) in the non-MA group. Mean
were observed in levels of fasting NEFA (Table 2). Thedifferences in albumin excretion between the first and
insulin-induced fall in NEFA levels during the hypergly-second 24-hour urine collections were 8.4  19.2 g/min
in the MA group and 0.14  2.75 g/min in the non- cemic clamp was similar in the groups, reflecting that
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Table 3. Glucose metabolism and insulin action in hypertensive
persons with and without microalbuminuria (MA)
Non-MA MA P value
Fasting glucose mmol/L 5.70.6 5.80.8 0.5
Fasting insulin pmol/L 7266 7064 0.9
Area under the glucose
curve mmol/L 14.15.1 13.95.6 0.9
Area under the insulin
curve pmol/L 1153837 1059696 0.6
1st phase insulin release
pmol/L 1097707 930594 0.5
2nd phase insulin release
pmol/L 1163702 1111662 0.6
Insulin sensitivity index 0.170.13 0.160.10 0.9
Glycosylated hemoglobin
A1c level % 5.70.5 5.70.5 0.9
Serum AGEs U/mL 7.93.5 11.03.0 0.05
Values are mean SD. Abbreviations are: non-MA, hypertensive persons with
microalbuminuria 20 g/min; MA, hypertensive persons with microalbuminuria
20 g/min; areas under the glucose and insulin curves; arbitrary incremental
area units over a 2-hour sampling time after an oral glucose tolerance test; 1st
phase insulin release, area under the insulin curve during the initial 10 minutes of
a hyperglycemic clamp; 2nd phase insulin release, area under the insulin curve dur-
ing 120 to 180 minutes of a hyperglycemic clamp; AGEs, serum levels of circulating
advanced glycation end products. Insulin sensitivity is calculated as mol · kg1 ·
min1 · pmol/L.
the insulin sensitivity for suppression of lipolysis was
comparable in the MA and non-MA groups (Table 2).
Coagulation and fibrinolytic factors
Fig. 1. Plasma glucose and insulin responses during 120 minutes afterNo differences in variables of the coagulation and the
ingestion of 75 g of dextrose in 26 hypertensive persons with urinaryfibrinolytic systems were observed (Table 2).
albumin excretion20 g/min () and in 32 hypertensive persons with
urinary albumin excretion 20 g/min ().
Glucose metabolism
Fasting plasma glucose and insulin concentrations were
not significantly different in the MA and non-MA groups
0.09). An additional euglycemic, hyperinsulinemic clamp(5.8  0.8 vs. 5.7  0.6 mmol/L, P  0.5, and 70  64
(EG) was done on 7 persons in the MA group and 12vs. 72  66 pmol/L, P  0.9, respectively). Increments
persons in the non-MA group to compare the insulinof glucose and insulin after ingestion of 75 g of dextrose
sensitivity indexes obtained by the two clamp techniques.were also similar in the groups (Table 3 and Fig. 1). The
The insulin sensitivity indexes obtained with EG wereglucose areas under the curve were 13.9  5.6 mmol/L
also similar in the two groups (0.06  0.03 vs. 0.08 in the MA group, and 14.1  5.1 mmol/L in the non-
0.04, P  0.7). Glycosylated hemoglobin A1c levels didMA group (P  0.9). The insulin areas under the curve
not differ in the groups, but serum levels of circulatingwere 1059  696 pmol/L in the MA group, and 1153 
AGEs were 11.0 3.0 U/mL in the MA group and 7.9837 pmol/L in the non-MA group (P  0.6). The insulin
3.5 U/mL in the non-MA group (P  0.05).responses to a three-hour glucose infusion, where the
plasma glucose concentration was kept at 10 mmol/L
Correlation parametersduring the hyperglycemic clamp, were similar in the
Pearson correlation coefficients and univariate regres-groups (Table 3 and Fig. 2). Insulin release during the
sion analyses with MA as the dependent variable wereinitial 10 minutes of the clamp (1st phase insulin release)
computed with all the variables shown in Tables 1, 2,were 930  594 pmol/L in the MA group and 1097 
and 3. Significant associations were only observed be-707 pmol/L in the non-MA group (P  0.5). The corre-
tween MA and systolic blood pressure (r  0.25, P sponding values for insulin release during the third hour
0.05, adjusted R 2 0.06), AGEs (r  0.27, P  0.05,of the clamp (2nd phase insulin release) were 1111  662
adjusted R 20.07) and smoking habits expressed asand 1163  702 pmol/L (P  0.6). The MA group and
number of cigarettes smoked per day (r  0.39, P the non-MA group also had a similar insulin sensitivity
0.01, adjusted R 20.10). Of these three variables, onlyindex (ISI): 0.16  0.10 and 0.17  0.13, respectively
(P  0.9). The groups were not insulin resistant (ISI the number of cigarettes smoked per day predicted MA
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metabolic variables could be detected between hyperten-
sive persons with high and low UAE (Table 4).
DISCUSSION
The present study did not find any associations be-
tween MA and metabolic variables linked to the insulin
resistance syndrome. The 26 hypertensive persons with
MA were not insulin resistant and had the same meta-
bolic profile as the well-matched, non-MA hypertensive
control group.
As previously shown [2, 11, 12], MA was associated
with elevated systolic blood pressure. MA correlates more
strongly with continuous ambulatory 24-hour blood pres-
sure than with office blood pressure readings [11]. The
recording of office blood pressure and the narrow range
of blood pressure may explain the rather weak associa-
tion found with MA in the present study. We also ob-
served a relationship between smoking and MA. Smok-
ing is known to be associated with MA in both diabetic
and non-diabetic subjects [46], probably mediated trough
endothelial damage [33]. AGEs bind to vascular collagen
and cause disturbances in the endothelial function [25].
The finding that MA was correlated with serum AGEs
may reflect that both relate to endothelial dysfunction.
However, neither hemostatic nor fibrinolytic variables
were altered in the MA group, as would be expected
Fig. 2. Plasma glucose levels, insulin responses, and glucose infusion with endothelial damage [33]. Since no relationships of
rates during a 180-minute hyperglycemic clamp performed in 26 hyper- MA with plasma glucose or glycosylated hemoglobin A1ctensive persons with urinary albumin excretion 20 g/min () and
were found, elevated glucose levels are probably not thein 32 hypertensive persons with urinary albumin excretion 20 g/min
(). Insulin concentrations during the initial 10 minutes of clamping (0 link between MA and AGEs.
to 10 min) reflects the first phase insulin release. Insulin concentrations Previous investigations have proposed that MA is a
during the third hour of clamping (120 to 180 min) reflects the second
consistent correlate to insulin resistance, hyperinsulin-phase insulin release.
emia, and dyslipidemia [13–15, 19, 47]. Many factors in-
fluence insulin sensitivity, such as body fat and fat distri-
bution [48], lipid profile [49], physical fitness [32], andindependently of the other variables, and adjusted R 2 in
smoking habits [31]. Insulin resistance has been founda multivariate model that included these three variables
to be associated with body fat rather than blood pressurewas only 0.12. The additional inclusion of age, gender,
[50], as is MA [14, 19, 27]. The association between MABMI, or insulin sensitivity index did not add significantly
and body weight [14, 19] and waist-to-hip ratio [27] hasto the model.
been shown to be independent of both blood pressure
Subanalyses and insulin sensitivity [19, 27]. Thus, the interrelation-
ships between body fat, fat distribution, blood pressureSince the urinary albumin excretion rate is a continu-
[2, 11], MA, and insulin sensitivity, may easily make dataous variable, and the cut-off point used to define MA
(20 g/min) may be debatable, we also compared the interpretations difficult in studies relating MA to insulin
sensitivity. Confounders are often not taken into accountmetabolic profile in the hypertensive subjects according
to the 25% MA quartile and the 75% MA quartile. The in study designs or insufficiently corrected for in data
analyses [15, 30, 47, 51].median urinary albumin excretion rate (UAE) in the
total study group was 15 g/min. The lowest quartile Insulin sensitivity assessed by the clamp technique has
been performed in a few case-control studies in non-had a UAE	8g/min (N 14), and the highest quartile
had a UAE 
 33 g/min (N  16). Gender distribution, diabetic subjects with MA [13, 19]. A limited number
(N  12 [19] and N  10 [13]) of highly selected micro-age, BMI, waist-to-hip ratio and creatinine levels were
similar in the high and low MA quartiles (P  0.3 for albuminuric, hypertensive persons on antihypertensive
treatment have been examined, and insulin-mediatedall). There tended to be more smoking in the highest
MA quartile (P  0.09). No significant differences in glucose uptake were found to be reduced by 35 [13] and
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Table 4. Blood pressure and metabolic profile in hypertensive subjects according to the 25% and 75% microalbuminuria (MA) quartile
25% MA quartile 75% MA quartile
MA	8 lg/min MA
33 lg/min P value
N 14 16
Median microalbumin excretion lg/min 7 (1–8) 50 (33–210)
Systolic blood pressure mm Hg 15013 15712 0.2
Diastolic blood pressure mm Hg 986 995 0.5
Fasting glucose mmol/L 5.80.8 6.00.9 0.4
Fasting insulin pmol/L 9290 6335 0.4
Area under the glucose curve mmol/L 14.45.9 16.25.9 0.4
Area under the insulin curve pmol/L 1206972 1032435 0.4
Insulin sensitivity index 0.160.13 0.130.07 0.9
Serum AGEs U/mL 8.55.3 10.24.8 0.10
Fibrinogen g/L 2.380.76 2.420.76 0.8
PAI-1 U/mL 10.06.9 15.29.6 0.3
tPA mU/mL 0.420.27 0.290.24 0.4
Triglycerides mmol/L 1.220.54 1.670.99 0.14
Total cholesterol mmol/L 5.931.14 6.270.63 0.3
LDL cholesterol mmol/L 4.120.71 4.100.73 0.8
Values are mean  SD unless in parentheses where it is MA range. Areas under the glucose and insulin curves are arbitrary incremental area units over a 2-hour
sampling time after an oral glucose tolerance test. Insulin sensitivity is calculated as mol · kg1 · min1 · pmol/L during a hyperglycemic clamp. Abbreviations are:
AGEs, serum levels of circulating advanced glycation end products; PAI-1, plaminogen activator inhibitor; tPA, tissue plasminogen activity; LDL, low-density
lipoprotein.
40 [19] percent. In the study of Bianchi et al, there was of the subgroup comparison of the highest and lowest MA
quartiles, however, may have been too small to detectan imbalance in smoking habits among the study groups
in an otherwise well conducted study [13], and the dis- discrete differences in variables linked with impaired
insulin action. This is not very likely since both groupscrepancies in findings of that study and the present study
are not readily understood. In the study of Agewall et had a high degree of insulin sensitivity according to the
values of the insulin sensitivity indices.al, the MA group was more obese than the control group
[19], which may explain the impaired insulin sensitivity Our results are consistent with the findings of the Hoorn
Study, a population study of 622 subjects where MA wasin the MA group. Furthermore, BMI predicted MA inde-
pendently of the insulin sensitivity index, and an inverse found to be associated with hypertension, but not the
insulin resistance syndrome [27]. Our results are also inrelationship between MA and insulin sensitivity index
(ISI) did not remain significant after an adjustment for agreement with a recent longitudinal study where the
investigators failed to find differences in the lipid profile,BMI [19]. This suggests that both MA and ISI were
related to BMI and not to each other, and demonstrates glucose and insulin concentrations, or blood pressure in
persistently microalbuminuric and normoalbuminuric non-the importance of correcting for the interrelationships
between ISI, BMI, and MA. Nielsen et al studied insulin diabetic subjects after a three-year follow-up period [28].
We found that MA in hypertension is not a marker ofsensitivity by applying the clamp technique in carefully
matched type II diabetics with and without MA, and metabolic derangements, provided confounding factors
such as the degree of obesity is controlled. As MA pre-found—as we did—a similar insulin sensitivity in the MA
and non-MA groups [52]. dicts increased risk of CAD in diabetic [4, 5] as well as
in non-diabetic populations [1, 3, 6–8, 53], the higher riskIn epidemiological studies insulin sensitivity is often
assessed on the basis of plasma insulin levels [6, 15, 16, 51]. of atherosclerosis in patients with MA should be medi-
ated through mechanisms other than impaired insulinInsulin levels vary with meals, degree and distribution of
body fat [50], lipid status [50], and the ability of the pan- sensitivity. MA may be a consequence of long-standing
hypertension with increased arteriolar and capillary hy-creatic beta cells to respond to insulin resistance with com-
pensatory hyperinsulinemia [10]. Thus, surrogate markers drostatic pressure and endothelial dysfunction [33, 54].
The observation that BMI is associated with MA inde-for insulin sensitivity based on plasma insulin levels may
be misleading, especially if variations in variables such pendently of blood pressure in hypertensive subjects
[29], indicates that vascular dysfunction and renal hyper-as BMI or central obesity are insufficiently corrected, as
is the case in some population studies [15, 51]. filtration also could be present because of other factors
than high blood pressure, such as overweight, smoking, orWe studied a fairly large group of untreated persons
with stable hypertension recruited from a population health genetic factors interfering with eg cytokines, growth fac-
tors, and the endothelial function. However, although notsurvey [34], using clamp technique to assess insulin sensi-
tivity. The results of the present study should therefore necessarily causally linked, obesity, hypertension, impaired
insulin sensitivity, and MA often coexist, and such individ-be applicable in the general population. The sample size
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